食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2014
◆商品コード:GMDHC5806IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:146
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction)の概要
・食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Adenocarcinoma of the Gastroesophageal Junction – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Adenocarcinoma Of The Gastroesophageal Junction – Pipeline Review, H2 2014’, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Adenocarcinoma Of The Gastroesophageal Junction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Adenocarcinoma Of The Gastroesophageal Junction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Adenocarcinoma Of The Gastroesophageal Junction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Adenocarcinoma of the Gastroesophageal Junction Overview 9
Therapeutics Development 10
Pipeline Products for Adenocarcinoma of the Gastroesophageal Junction – Overview 10
Pipeline Products for Adenocarcinoma of the Gastroesophageal Junction – Comparative Analysis 11
Adenocarcinoma of the Gastroesophageal Junction – Therapeutics under Development by Companies 12
Adenocarcinoma of the Gastroesophageal Junction – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Adenocarcinoma of the Gastroesophageal Junction – Products under Development by Companies 17
Adenocarcinoma of the Gastroesophageal Junction – Companies Involved in Therapeutics Development 19
AlphaMab Co., Ltd 19
Amgen Inc. 20
Apceth GmbH & Co. KG 21
ArQule, Inc. 22
AstraZeneca PLC 23
Boehringer Ingelheim GmbH 24
Boston Biomedical, Inc. 25
Bristol-Myers Squibb Company 26
Cerulean Pharma, Inc. 27
Eli Lilly and Company 28
Epirus Biopharmaceuticals, Inc. 29
F. Hoffmann-La Roche Ltd. 30
Ganymed Pharmaceuticals AG 31
Genentech, Inc. 32
Mebiopharm Co., Ltd. 33
Merck & Co., Inc. 34
Millennium Pharmaceuticals, Inc. 35
Novartis AG 36
Panacea Biotec Limited 37
Sanofi 38
Supratek Pharma Inc. 39
Adenocarcinoma Of the Gastroesophageal Junction – Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Target 41
Assessment by Mechanism of Action 43
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
Agenmestencel-T – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
AMG-337 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AZD-4547 – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
BBI-608 – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
BI-853520 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
BMS-833923 – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
cabazitaxel – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
CRLX-101 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
dovitinib lactate – Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
doxorubicin – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
emibetuzumab – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
erismodegib – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
IMAB-362 – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
ipatasertib – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MBP-426 – Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
MLN-0264 – Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
panitumumab – Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
pembrolizumab – Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
ramucirumab – Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
rilotumumab – Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
solitomab – Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
tivantinib – Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
trastuzumab biosimilar – Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
trastuzumab biosimilar – Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
trastuzumab biosimilar – Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
trastuzumab biosimilar – Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
trastuzumab emtansine – Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
trebananib – Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Adenocarcinoma Of the Gastroesophageal Junction – Recent Pipeline Updates 108
Adenocarcinoma Of the Gastroesophageal Junction – Dormant Projects 142
Adenocarcinoma Of the Gastroesophageal Junction – Discontinued Products 143
Adenocarcinoma Of the Gastroesophageal Junction – Product Development Milestones 144
Featured News & Press Releases 144
Jul 22, 2014: Ganymed Completes Recruitment for Randomized Phase 2 FAST Trial of IMAB362 for Gastroesophageal Cancer 144
Appendix 145
Methodology 145
Coverage 145
Secondary Research 145
Primary Research 145
Expert Panel Validation 145
Contact Us 146
Disclaimer 146

[List of Tables]
Number of Products under Development for Adenocarcinoma of the Gastroesophageal Junction, H2 2014 10
Number of Products under Development for Adenocarcinoma of the Gastroesophageal Junction - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Development by Companies, H2 2014 (Contd..1) 18
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by AlphaMab Co., Ltd, H2 2014 19
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2014 20
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Apceth GmbH & Co. KG, H2 2014 21
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2014 22
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by AstraZeneca PLC, H2 2014 23
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2014 24
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2014 25
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2014 26
Adenocarcinoma Of the Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2014 27
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2014 28
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 29
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 30
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2014 31
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Genentech, Inc., H2 2014 32
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2014 33
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2014 34
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 35
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Novartis AG, H2 2014 36
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2014 37
Adenocarcinoma of the Gastroesophageal Junction - Pipeline by Sanofi, H2 2014 38
Adenocarcinoma Of the Gastroesophageal Junction - Pipeline by Supratek Pharma Inc., H2 2014 39
Assessment by Monotherapy Products, H2 2014 40
Number of Products by Stage and Target, H2 2014 42
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 46
Number of Products by Stage and Molecule Type, H2 2014 48
Adenocarcinoma Of the Gastroesophageal Junction Therapeutics - Recent Pipeline Updates, H2 2014 108
Adenocarcinoma Of the Gastroesophageal Junction - Dormant Projects, H2 2014 142
Adenocarcinoma Of the Gastroesophageal Junction - Discontinued Products, H2 2014 143

[List of Figures]
Number of Products under Development for Adenocarcinoma of the Gastroesophageal Junction, H2 2014 10
Number of Products under Development for Adenocarcinoma of the Gastroesophageal Junction - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Assessment by Monotherapy Products, H2 2014 40
Number of Products by Top 10 Targets, H2 2014 41
Number of Products by Stage and Top 10 Targets, H2 2014 41
Number of Products by Top 10 Mechanism of Actions, H2 2014 43
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 43
Number of Products by Top 10 Routes of Administration, H2 2014 45
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 46
Number of Products by Top 10 Molecule Types, H2 2014 47
Number of Products by Stage and Top 10 Molecule Types, H2 2014 48

【掲載企業】

AlphaMab Co., Ltd
Amgen Inc.
Apceth GmbH & Co. KG
ArQule, Inc.
AstraZeneca PLC
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cerulean Pharma, Inc.
Eli Lilly and Company
Epirus Biopharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Ganymed Pharmaceuticals AG
Genentech, Inc.
Mebiopharm Co., Ltd.
Merck & Co., Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Panacea Biotec Limited
Sanofi
Supratek Pharma Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[食道胃接合部腺がん(Adenocarcinoma Of The Gastroesophageal Junction):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆